Previous 10 | Next 10 |
2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023. Webcast and Conference Call and Details Investors may...
2023-04-16 05:21:00 ET Are you looking for stocks that can make dramatic moves in a short amount of time? If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR) . SVB Securities, a subsidiary of SVB Financial , recently gave the stock an upgrade to outperform a...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 8.51% on the day to $30.99. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable disease...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 11.02% on the day to $29.12. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseas...
2023-04-12 12:09:05 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) jumped ~11% Wednesday after SVB Securities upgraded the RNAi therapeutics company to Outperform from Market Perform, citing an attractive risk-reward setup following the recent selloff. The analyst Mani Forooh...
2023-04-12 10:03:10 ET Gainers: Altamira Therapeutics ( CYTO ) +74% . Arrowhead Pharmaceuticals ( ARWR ) +11% . Procaps Group ( PROC ) +11% . Tempest Therapeutics ( TPST ) +11% . Meihua International Medical Technologies ( MHUA )...
- Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET i...
2023-04-11 07:12:52 ET Summary Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics and has a diverse clinical pipeline and strong industry partnerships. Arrowhead appears undervalued compared to industry counterparts, suggesting potential for increased valuation as i...
2023-04-04 08:18:16 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) will receive a $40M milestone payment from Takeda Pharmaceutical ( NYSE: TAK ) as the Japanese patient dosed the first patient in a phase 3 trial of fazirsiran to treat alpha-1 antitrypsin deficiency associa...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...